Liu et al.
that of the native mitochondrial MnSOD.6a,8g At the same
time, these complexes are the first enzyme mimetics tested
in humans.
Scheme 1
In the case of the macrocyclic MnII mimetics (Scheme 1),
it has been postulated that the profound conformational
rearrangements of the macrocyclic pentadentates facilitate
subsequent electron transfer and that the ligands with high
conformational flexibility can assist SOD activity.8a,g Seven-
coordinate FeIIISOD mimetics with the same macrocyclic
chelate systems show a different catalytic mechanism in
which the aqua-hydroxo form of the complex, [Fe(L)(OH)-
(H2O)]2+, is the catalytically active species.11 A drawback
of these complexes is the low-pKa values of the two
coordinated water molecules, which results in the formation
of inactive (inert) dihydroxo complexes at the physiological
pH.11 Therefore, the idea is to design a chelate that will
decrease the acidity of the iron center and so increase the
concentration of the catalytically active aqua-hydroxo
species at the physiological pH to promote an enhanced SOD
activity. Because free iron ions are more toxic than manga-
nese ions,5 it is important that the chelate will form a very
stable complex and prevent the release of iron ions. Despite
this toxicity, complexes of FeIII would be highly attractive
as SOD mimetics because of their higher kinetic and
thermodynamic stability than MnII complexes.
Because we have shown that the conformational flexibility
of the pentadentate ligand is not a key requirement for the
SOD activity of the seven-coordinate complexes, due to the
fact that in an interchange substitution mechanism (operating
in the case of these complexes)12a efficient formation of a
real six-coordinate (with pseudo octahedral geometry) in-
termediate is generally not required, we were interested in
additional experimental validation of such a mechanistic
paradigm. This has been achieved by probing the reactivity
of appropriate conformationally inflexible complexes toward
superoxide.
candidates primarily from immunogenic response.2a,3a,4a,5 This
calls for new types of free-radical inhibiting enzyme mimetics
to be used as pharmaceuticals. Stable low molecular weight
metal complexes that can react with superoxide and ef-
ficiently replicate the activity of the native SOD enzyme have
the potential to become a new generation of drugs for the
treatment of diseases of various aetiologies.2b,3a,4a,5,6
Among the many different complexes that have been
studied as potential SOD mimetics,2b,3a,5,6b,7 the most efficient
synthetic SOD catalysts known to date are seven-coordinate
complexes of MnII with macrocyclic pentadentate chelates
derived from carbon-substituted pentaazacyclopentadecane
[15]aneN5 (Scheme 1).2b,3a,4a,5,6a,8 Their catalytic rate constants
were obtained by direct kinetic measurements, as the only
reliable method for quantitative assessment of activity,9,10
showing that the SOD activity of these complexes can exceed
(5) Riley, D. P. Chem. ReV. 1999, 99, 2573-2587 and references cited
therein.
(6) (a) Salvemini, D.; Wang, Z.-Q.; Zweier, J. L.; Samouilov, A.;
Macarthur, H.; Misko, T. P.; Currie, M. G.; Cuzzocrea, S.; Sikorski,
J. A.; Riley, D. P. Science 1999, 286, 304-306. (b) Vujaskovic, Z.;
Batinic-Haberle, I.; Rabbani, Z. N.; Feng, Q.-F.; Kang, S. K.;
Spasojevic, I.; Samulski, T. V.; Fridovich, I.; Dewhirst, M. W.;
Anscher, M. S. Free Radical Biol. Med. 2002, 33, 857-863 and
references cited therein. (c) Samlowski, W. E.; Petersen, R.; Cuzzocrea,
S.; Macarthur, H.; Burton, D.; McGregor, J. R.; Salvemini, D. Nat.
Med. 2003, 9, 750-755. (d) Okado-Matsumoto, A.; Batinic-Haberle,
I.; Fridovich, I. Free Radical Biol. Med. 2004, 37, 401-410.
(7) (a) Batinic-Haberle, I.; Spasojevic, I.; Hambright, P.; Benov, L.;
Crumbliss, A. L.; Fridovich, I. Inorg. Chem. 1999, 38, 4011-4022.
(b) Ohtsu, H.; Shimazaki, Y.; Odani, A.; Yamauchi, O.; Mori, W.;
Itoh, S.; Fukuzumi, S. J. Am. Chem. Soc. 2000, 122, 5733-5741. (c)
Li, D.; Li, S.; Yang, D.; Yu, J.; Huang, J.; Li, Y.; Tang, W. Inorg.
Chem. 2003, 42, 6071-6080. (d) Durackova, Z.; Labuda, J. J. Inorg.
Biochem. 1995, 58, 297-303. (e) Liao, Z.; Xiang, D.; Li, D.; Mei,
F.; Yun, F. Synth. React. Inorg. Met.-Org. Chem. 1998, 28, 1327-
1341. (f) Spasojevic´, I.; Batinic´-Haberle, I.; Stevens, R. D.; Hambright,
P.; Thorpe, A. N.; Grodkowski, J.; Neta, P.; Fridovich, I. Inorg. Chem.
2001, 40, 726-739. (g) Yamaguchi, S.; Kumagai, A.; Funahashi, Y.;
Jitsukawa, K.; Masuda, H. Inorg. Chem. 2003, 42, 7698-7700. (h)
Batinic´-Haberle, I.; Spasojevic´, I.; Stevens, R.; Hambright, D.; Neta,
P.; Okado-Matsumoto, A.; Fridovich, I. J. Chem. Soc., Dalton Trans.
2004, 1696-1702. (i) Shearer, J.; Long, L. M. Inorg. Chem. 2006,
45, 2358-2360. (j) Durot, S.; Lambert, F.; Renault, J.-P.; Policar, C.
Eur. J. Inorg. Chem. 2005, 2789-2793.
In this paper, we have synthesized and characterized seven-
coordinate FeII (2) and MnII (3) complexes of acyclic and
rigid pentadentate H2dapsox [H2dapsox ) 2,6-diacetylpyri-
dinebis(semioxamazide)]12b that have several important
features regarding their potential SOD activity. The reactivity
of these two complexes and the previously reported FeIII
complex (1) of the same ligand12c-e (all of which have the
structure shown in Scheme 2) toward superoxide has been
studied spectrophotometrically, electrochemically, and by a
submillisecond mixing UV/vis stopped-flow in DMSO. The
(10) Weiss, R. H.; Flickinger, A. G.; Rivers, W. J.; Hardy, M. M.; Aston,
K. W.; Ryanll, U. S.; Riley, D. P. J. Biol. Chem. 1993, 268 (31),
23049.
(11) Zhang, D.; Busch, D. H.; Lennon, P. L.; Weiss, R. H.; Neumann, W.
L.; Riley, D. P. Inorg. Chem. 1998, 37, 956-963 and references cited
therein.
(12) (a) Dees, A.; Zahl, A.; Puchta, R.; van Eikema Hommes, N. J. R.;
Heinemann, F. W.; Ivanovic-Burmazovic, I. Inorg. Chem. 2007, 46,
2459-2470. (b) Andjelkovic, K.; Ivanovic, I.; Prelesnik, B. V.; Leovac,
V. M.; Poleti, D. Polyhedron 1996, 15 (24), 4361-4366. (c)
Andjelkovic, K.; Bacchi, A.; Pelizzi, G.; Jeremic, D.; Ivanovic-
Burmazovic, I. J. Coord. Chem. 2002, 55, 1385-1392. (d) Ivanovic-
Burmazovic, I.; Hamza, M. S. A.; van Eldik, R. Inorg. Chem. 2002,
41, 5150-5161. (e) Ivanovic-Burmazovic, I.; Hamza, M. S. A.; van
Eldik, R. Inorg. Chem. 2006, 45, 1575-1584.
(8) (a) Riley, D. P.; Weiss, R. H. J. Am. Chem. Soc. 1994, 116, 387-
388. (b) Riley, D. P.; Henke, S. L.; Lennon, P. J.; Weiss, R. H.;
Neumann, W. L.; Rivers, W. J.; Aston, K. W.; Sample, K. R.; Rahman,
H.; Ling, C.-S.; Shieh, J.-J.; Busch, D. H.; Szulbinski, W. Inorg. Chem.
1996, 35, 5213-5231. (c) Riley, D. P.; Lennon, P. J.; Neumann, W.
L.; Weiss, R. H. J. Am. Chem. Soc. 1997, 119, 6522-6528. (d) Riley,
D. P.; Henke, S. L.; Lennon, P. J.; Aston, K. Inorg. Chem. 1999, 38,
1908-1917. (e) Riley, D. P. AdV. Supramol. Chem. 2000, 6, 217-
244. (f) Kra¨mer, R. Angew. Chem. 2000, 112, 4641-4642; Angew.
Chem., Int. Ed. 2000, 39, 4469-4470. (g) Aston, K.; Rath, N.; Naik,
A.; Slomczynska, U.; Schall, O. F.; Riley, D. P. Inorg. Chem. 2001,
40, 1779-1789.
(9) Riley, D. P.; Rivers, W. J.; Weiss, R. H. Anal. Biochem. 1991, 196,
344-349.
8826 Inorganic Chemistry, Vol. 46, No. 21, 2007